The Menopause Microbiome: What Oestrogen Has to Do With Vaginal pH, Good Bacteria and Recurrent Symptoms

What is the vaginal microbiome?

The vaginal microbiome is the changing community of microorganisms living in the vaginal environment and the genes and conditions around them. Most research focuses on bacteria, although fungi, viruses and other organisms belong to the wider ecosystem. A healthy vagina is therefore not sterile, and bacterial presence is not evidence of dirt or disease.

Composition differs between women and can change within the same woman. Hormones, menstruation, semen, sexual activity, medicines, pregnancy, infection, hygiene practices and sampling methods can influence what a study detects. One swab is a snapshot, not a permanent identity.

Foundational sequencing work described several recurring community patterns among healthy reproductive-age women. Some were dominated by different Lactobacillus species; another contained more diverse anaerobic communities. The important lesson is that no single exact microbial profile defines health for everybody.

Why Lactobacillus gets so much attention

Several Lactobacillus species produce lactic acid, support a lower vaginal pH and interact with epithelial and immune systems. They may also compete with other organisms for space and resources. These are plausible protective functions, not proof that every product containing Lactobacillus prevents disease.

Lactobacillus is a genus rather than one interchangeable organism. L. crispatus, L. iners, L. gasseri and L. jensenii differ biologically. L. crispatus is often associated with stability, while L. iners can appear across changing states. A label saying only ‘contains Lactobacillus’ gives little clinical information without strain-level evidence.

‘Good bacteria’ is useful shorthand but poor medical strategy. Microorganisms behave according to host, community and context. Health cannot be reduced to maximising one count.

pH is chemistry, not cleanliness

pH measures acidity or alkalinity. During reproductive years the vagina is often relatively acidic, partly because Lactobacillus-produced lactic acid contributes to the environment. Menstrual blood, semen, hormones, medicines and infection can alter a measurement.

After menopause, pH often rises as the oestrogen-responsive tissue environment changes and Lactobacillus dominance becomes less common in many people. The British Menopause Society describes this rise and shift in flora within the broader biology of genitourinary syndrome of menopause.

A pH result is not a cleanliness score and cannot identify a cause alone. Higher pH occurs with bacterial vaginosis, but can also reflect menopause-associated change. Home testing cannot reliably separate GSM, BV, irritation, an STI or other causes.

How oestrogen, tissue and microbes interact

The familiar pathway runs from oestrogen to epithelial maturation and glycogen, then Lactobacillus and lactic acid. It is a useful framework, but modern science shows a network involving host cells, glycogen breakdown products, bacterial metabolism, immune signalling and the wider microbial community.

As oestrogen falls, vaginal epithelium may become thinner and less glycogen-rich, while secretions and tissue resilience change. In many—but not all—postmenopausal women, studies find less Lactobacillus dominance, greater diversity and higher pH.

This is association rather than a deterministic chain. Local or systemic oestrogen, individual biology, sexual activity, medicines, health conditions and study methods all influence observations. Menopause changes the habitat; it does not create one identical microbial outcome.

GSM and the microbiome: cause, consequence or both?

Genitourinary syndrome of menopause describes symptoms and tissue changes associated with oestrogen deficiency across the vulva, vagina, bladder and urethra. Dryness, burning, irritation, painful sex and urinary discomfort may occur. Microbial shifts happen within that altered environment.

Associations exist between microbial patterns, pH, examination findings and symptoms, but causality is not simple. A 2023 review found that postmenopausal symptom biology remains incompletely understood and that interventions changing microbiota or pH do not consistently improve symptom severity.

A person can have a non-Lactobacillus-dominant community without symptoms, or severe symptoms not explained by one pattern. GSM should not be reduced to dysbiosis.

Why symptoms can feel like infection

Burning, soreness, painful sex, urinary discomfort and discharge change can occur with GSM. Similar symptoms arise with BV, candidiasis, an STI, urinary infection, vulval skin disease, contact irritation and other conditions.

This overlap encourages repeated self-treatment. Symptoms may fluctuate, an antifungal base may briefly soothe irritation, or one episode genuinely may have been thrush. None proves every recurrence has the same cause.

Persistent symptoms need clinical context and targeted testing where appropriate. A microbiome list cannot decide which organism is causing symptoms—or whether the main problem is microbial.

Bacterial vaginosis after menopause

BV involves a shift from Lactobacillus-dominant flora towards more diverse anaerobic communities. Discharge or odour may change, elevated pH is common and recurrence is frequent. Diagnosis uses clinical or laboratory criteria rather than pH alone.

Menopause complicates interpretation because pH can already be higher and Lactobacillus less abundant without BV. Tests developed mainly in reproductive-age populations require careful clinical correlation after menopause.

A high postmenopausal pH does not automatically mean BV. New or persistent odour or discharge deserves assessment, especially when treatment repeatedly fails, but not automatically another balancing product.

Thrush is not a bacterial imbalance

Candida is a fungus, and colonisation can occur without symptomatic vulvovaginal candidiasis. Detection does not automatically explain itching, burning or discharge; clinical and testing context matter.

GSM, dermatitis, lichen sclerosus and other causes can mimic thrush. Repeated empirical antifungal treatment can delay diagnosis and irritate sensitive vulval skin.

Bacterial communities may interact with Candida ecology, but complexity does not make a retail probiotic a proven antifungal. Evidence for preventing or treating recurrent candidiasis remains product- and study-specific.

The vaginal ecosystem and recurrent UTI

The vagina and urethra are close ecological neighbours. A Lactobacillus-rich environment may reduce opportunities for some uropathogens to colonise around the urethra, while menopause-associated tissue and microbial change may contribute to UTI susceptibility.

This is one part of a broader picture including bladder emptying, prolapse, sexual activity, diabetes and urinary tract abnormalities. UTI-like symptoms may instead reflect GSM or another bladder or vulval condition.

NICE recommends considering vaginal oestrogen for recurrent UTI in the relevant menopause context when behavioural and personal measures are ineffective or inappropriate. Vaginal probiotics are not equivalent to established prevention pathways.

Does vaginal oestrogen change the microbiome?

Studies commonly report that local oestrogen improves epithelial maturation, lowers pH and increases Lactobacillus abundance in many postmenopausal women. This fits the model of restoring a tissue environment in which Lactobacillus can thrive.

Clinical benefit and microbiome change remain distinct. Symptoms may improve without one ideal community appearing, and oestrogen does not relieve discomfort for everyone. A laboratory shift is not the sole treatment target.

NICE recommends vaginal oestrogen for menopause-associated genitourinary symptoms, including in systemic-HRT users. Suitability, preference, unexplained bleeding and breast-cancer context still require individual discussion.

Do vaginal probiotics work?

‘Probiotic’ is not one treatment. Evidence must specify strain, combination, dose, route, duration, formulation and condition. Results from one product cannot be transferred automatically to another label containing Lactobacillus.

For BV, some trials suggest selected probiotics may help as adjuncts or reduce recurrence, but findings vary and standard treatment remains diagnosis-led antimicrobial care. Evidence for recurrent thrush, GSM and recurrent UTI is more limited or inconsistent.

A 2025 menopause-transition review found potentially favourable signals but judged included studies at high risk of bias and disclosed substantial commercial conflicts. Oral and vaginal routes are not interchangeable, and colony-forming-unit counts do not prove a clinical outcome.

Food, washes and pH-balancing products

Yoghurt, kefir and fermented foods can form part of a varied diet, but direct evidence that a particular food restores vaginal flora is limited. Food should never be inserted vaginally; it is not a controlled medicine and may irritate or introduce contamination.

‘pH-balancing’ is a marketing category, not a diagnosis. Lactic-acid gels, boric-acid products, moisturisers, washes and deodorants have different evidence and risks. Changing pH does not automatically treat the cause.

Boric acid has selected specialist uses in recurrent or resistant conditions, but is toxic if swallowed and unsuitable in some circumstances. Online availability is not proof of suitability.

Douching: when cleaner becomes less healthy

The vagina cleans itself through normal secretions and does not need internal washing. Douching can disturb local ecology, introduce irritants and is associated with BV and other adverse outcomes. There is no routine health need to douche.

The vulva is external and can be washed gently. Warm water or a suitable unperfumed soap substitute may suit sensitive skin; individual advice matters with dermatitis or another condition. Fragranced washes and deodorants can aggravate irritation.

Odour is not evidence of poor hygiene. Normal scent varies with sweat, discharge and sex. A strong new or persistent change needs assessment rather than increasingly aggressive cleansing.

At-home microbiome tests: useful science or premature medicine?

Consumer tests may sequence species, report relative abundance, measure pH or screen selected organisms. The technology can generate interesting data, but clinical interpretation is much harder than producing a colourful profile.

Swab location, recent sex or treatment, day-to-day fluctuation and reference populations affect results. Thresholds linking a pattern to symptoms or treatment are often uncertain. Detecting an organism does not show that it causes disease.

Consumer profiling differs from targeted clinical microbiology designed to answer a specific question. It cannot replace assessment for BV, candidiasis, STI, UTI, GSM, skin disease or unexplained bleeding.

What does dysbiosis mean?

Dysbiosis broadly describes a microbial community considered disrupted or associated with disease. It can be useful in research, but commercial language often turns it into a diagnosis with a matching product.

A community unlike a Lactobacillus-dominant reference is not automatically unhealthy. Healthy women have different structures, and postmenopausal ecology differs from reproductive-age ecology. Diversity is not universally good or bad; meaning depends on site and context.

Population differences have been reported, but race is not a simple biological microbiome category. Social, environmental, behavioural, genetic and methodological influences overlap, and findings must not label one group’s community as superior.

The microbiome is not the whole vaginal-health story

Microbiome language can become a shortcut. Burning may arise from GSM, dermatitis, lichen sclerosus, infection, pelvic-floor dysfunction, urinary disease, irritants or persistent pain conditions. Painful sex or discharge may require broader assessment.

The danger is not microbiome research; it is using emerging science to replace differential diagnosis. A test can create false certainty and lead to unnecessary antibiotics, antifungals, acids or supplements.

Assessment matters for recurrent symptoms despite treatment, persistent odour or discharge, skin change, painful sex, urinary symptoms, repeated BV or presumed thrush, symptoms after a new exposure, and any unexplained bleeding or blood-stained discharge.

Oral versus vaginal probiotics

Route is part of the intervention, not a packaging detail. A vaginal preparation reaches the local environment directly, while an oral organism must survive manufacturing, storage and digestion before any proposed effect on vaginal ecology. Evidence from one route cannot simply be assigned to the other.

Strain identity matters just as much. Organisms sharing a genus or species name can have different functional characteristics, and multi-strain combinations create uncertainty about which component matters. Commercial formulations may change while the broad label remains similar.

A large colony-forming-unit number does not prove viability at use, colonisation or benefit. Outcomes such as symptom improvement and recurrence matter more than a laboratory count.

Probiotic research remains important, but recommendations must follow the exact tested intervention and diagnosis. A probiotic should not delay testing, replace established treatment or become a universal maintenance requirement.

Odour, discharge and normal variation

Discharge changes across the life course. Hormones, sexual activity, medicines and tissue health can affect amount or consistency. After menopause, new persistent discharge deserves attention because GSM is only one possible explanation.

Odour exists on a spectrum. Sweat, discharge, semen and external skin alter normal scent. A new persistent fishy smell may occur with BV, but odour alone is not a home diagnostic test; infection, a retained foreign body and other causes may need consideration.

Blood-stained discharge, bleeding after sex or any postmenopausal bleeding should not be labelled a microbiome fluctuation. These require assessment. Heavy bleeding, severe pain, fever or systemic illness may need more urgent help.

Repeated deodorising can obscure rather than solve the issue. Fragrance may irritate vulval tissue, while internal products can change pH without treating the cause. Targeted assessment is more informative than trying to remove every natural scent.

Systemic HRT and the vaginal ecosystem

Systemic HRT may influence vaginal tissue and microbial ecology in some women, but responses are variable. Improvement in hot flushes, sleep or mood does not guarantee that dryness, burning or urinary discomfort will resolve, and a systemic prescription should not be judged solely by a microbiome profile.

Local and systemic oestrogen are not microbiologically or clinically interchangeable. Vaginal oestrogen delivers treatment to local tissues and is specifically recommended by NICE for menopause-associated genitourinary symptoms, including in people already using systemic HRT.

A persistent symptom should prompt a local assessment rather than an automatic systemic dose change. Infection, a vulval dermatosis, pelvic-floor dysfunction and other causes can coexist with GSM. The response to one treatment provides information but does not prove that every remaining symptom has the same mechanism.

Research comparing formulations, doses and routes remains heterogeneous. It is therefore safer to describe likely tissue and community effects than promise one predictable microbiome outcome from HRT.

Timing also matters. Tissue responses develop over time, while sampling performed soon after antibiotics, antifungals, sex or another vaginal product may capture a temporary state. A single before-and-after result should not be treated as proof of a permanent ecological reset or used to override how the person actually feels.

Clinical review should centre symptoms, examination findings where appropriate, treatment tolerance and the person’s goals. Microbiome measures may enrich future care, but they should support rather than displace these established outcomes.

What research still does not tell us

Studies differ in recruitment, menopause and symptom definitions, sampling, sequencing and analysis. Small cohorts and cross-sectional designs can reveal associations without showing what changed first.

Many studies underrepresent older women, varied hormone regimens and diverse social or ethnic groups. Population findings can then be mistaken for universal rules. Better longitudinal research must follow individuals before, through and after menopause.

Intervention trials need clinical outcomes. A product may lower pH or change relative abundance without reducing pain, irritation, BV recurrence or UTI. Symptoms may improve through tissue effects without creating a predefined ideal community.

Future microbiome therapeutics may become useful when precise strains and indications are rigorously studied. For now, curiosity should coexist with diagnostic restraint: we know enough to reject hygiene myths, but not enough to prescribe one perfect ecosystem.

What actually supports vaginal health after menopause?

Avoid unnecessary internal cleansing and irritants. Seek assessment when symptoms persist or recur. Treat confirmed infection appropriately, address GSM when present and manage vulval skin or pelvic-floor conditions according to diagnosis.

Moisturisers or lubricants may help appropriate symptoms. Vaginal oestrogen is evidence-based for menopause-associated genitourinary symptoms when suitable. Neither requires a consumer microbiome score.

The goal is not a perfect microbiome. It is comfortable, healthy tissue; accurate treatment of disease; and freedom from the idea that the vagina must be constantly cleansed, tested or corrected.